Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, +22

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaElderly PatientsMedicineBi-weekly Chop-14 +5

Human neoplasms elicit multiple specific immune responses in the autologous host.

Uğur Şahin, Ö. Türeci, Holger Schmitt, +7

Proceedings of the National Academy of Sciences

ImmunologyPathologyEscherichia ColiAntigen ProcessingImmune System +16

Deregulated T Cell Activation and Autoimmunity in Mice Lacking Interleukin-2 Receptor β

Haruhiko Suzuki, Thomas M. Kündig, Caren Furlonger, +10

Science

T-regulatory CellImmunologyImmune RegulationT CellsImmune System +15

Distinct Roles for LFA-1 and CD28 during Activation of Naive T Cells: Adhesion versus Costimulation

Martin F. Bachmann, Kim McKall-Faienza, Rudolf Schmits, +5

Immunity

Autoimmune DiseaseNaive T CellsAdaptive Immune SystemImmunologyImmune Regulation +8

CD44 Regulates Hematopoietic Progenitor Distribution, Granuloma Formation, and Tumorigenicity

Rudolf Schmits, Jorge Filmus, Nicole Gerwin, +14

Blood

MSH2 deficient mice are viable and susceptible to lymphoid tumours

Armin Reitmair, Rudolf Schmits, Amy Ewel, +13

Nature Genetics

Lymphoid NeoplasiaMsh2 Deficient MiceLymphocyte DevelopmentImmunologyLymphatic System +4

Impaired Negative Selection of T Cells in Hodgkin's Disease Antigen CD30–Deficient Mice

Ryuichi Amakawa, Anne Hakem, Thomas M. Kündig, +12

Cell

Lymphocyte DevelopmentImmune RegulationImmunologyT Cell ImmunityCd4 T Cell Responses +5

LFA-1-deficient mice show normal CTL responses to virus but fail to reject immunogenic tumor.

Rudolf Schmits, Thomas M. Kündig, D. Baker, +10

The Journal of Experimental Medicine

Immunogenic TumorImmunologyPathologyImmunologic MechanismImmune System +14

Treatment Results in Localized Primary Gastric Lymphoma: Data of Patients Registered Within the German Multicenter Study (GIT NHL 02/96)

P. Koch, Andreas Probst, Wolfgang E. Berdel, +17

Journal of Clinical Oncology

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada, +203

The Lancet Oncology

Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma +5